Home > Newsletters > The QMN Weekly Bulletin > Supplier Glass Vial Defects Prompt Warning on Hospira Cancer Drug
The QMN Weekly Bulletin
July 20, 2012 | Vol. 4 No. 29
Supplier Glass Vial Defects Prompt Warning on Hospira Cancer Drug
Hospira is looking into a supplier glass defect following consumer complaints and a Health Canada warning to physicians not to use three lots of its cancer treatment paclitaxel injection, 300 mg/50 mL.
Complaints to the company from outside Canada described particles embedded in the glass vial, rust-like marks on the vial and particles in the solution, the agency said. Hospira to date has not received any adverse event complaints for the lots.
“Preliminary root cause findings attribute this issue to a supplier glass defect,” Hospira spokesman Dan Rosenberg said. The company is working with customers and the agency to resolve the issue and take preventive actions, he added. Hospira has also agreed not to release further inventory from the three lots but a shortage situation is not anticipated, Health Canada said.
How can you ensure your suppliers’ goods are top notch? At FDAnews, we hear questions like this every day from drugmakers.
And questions like this are only going to get more complicated. Congress recently gave the FDA expanded authority under GMPs to police supplier quality agreements. What will that mean for you? In fact, what are the answers to all your supplier quality questions?
Attend FDAnews’ Fourth Annual Supplier Quality Management Congress this July 31-Aug. 2.
Get three days and two nights of face-to-face interchange with top regulators and policymakers, industry experts, lawyers and consultants discussing hat actions are being taken to strengthen the international supply chain.
This congress is the opportunity you’ve been looking for. Make sure you reserve yourself a spot and we’ll see you there.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.